Compugen Reports Second Quarter 2019 Results

Go back to Compugen Reports Second Quarter 2019 Results

Compugen (CGEN) Tops Q2 EPS by 4c

August 5, 2019 7:06 AM UTC

Compugen (NASDAQ: CGEN) reported Q2 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14).

"We continued the strong execution of our clinical program throughout the second quarter of 2019," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. "This includes the important milestone of first patient dosed in the combination arm of our Phase 1 study of COM701 and Opdivo®, which remains on-track to complete enrollment this year. Additionally, the COM701 monotherapy dose escalation arm is progressing,... More